Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy.

ABSTRACT: Immunotherapy has revolutionized cancer treatment. Immune-checkpoint inhibitors, on balance, showed a favorable efficacy/toxicity profile with durable response in different cancer types. No predictive biomarker has been validated thus far to select patients who would benefit from therapy. Among the candidate predictive biomarkers, mismatch repair status of the tumor is currently one of the most promising. Indeed, tumors displaying mismatch repair deficiency or microsatellite instability showed remarkable response to immunotherapy in clinical trials. This correlation has been first reported in colorectal cancers, but similar results have been observed also in other cancer types. The possible mechanism behind this correlation may be the higher mutational load observed in mismatch repair defi

SUBMITTER: Viale G 

PROVIDER: S-EPMC5523547 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature